Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)

Journal:

American Journal of Respiratory and Critical Care Medicine

Published:

2026-05-01

DOI:

10.1093/ajrccm/aamag031

Affiliations:

14

Authors:

13

Go to article

Institutions	Authors	Share
GSK, United Kingdom (UK)	2.000000	0.15
Yale University, United States of America (USA)	1.000000	0.08
Teikyo University, Japan	1.000000	0.08
University Hospital Bonn (UKB), Uni Bonn, Germany	1.000000	0.08
International Center for Infectiology Research (CIRI), France	1.000000	0.08
Quebec Heart and Lung Institute (IUCPQ), UL, Canada	1.000000	0.08
University of Wisconsin-Madison (UW-Madison), United States of America (USA)	1.000000	0.08
Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, United Kingdom (UK)	1.000000	0.08
National Jewish Health (NJH), United States of America (USA)	1.000000	0.08
GlaxoSmithKline R&D Bangalore, India	1.000000	0.08
University of Oxford, United Kingdom (UK)	1.000000	0.08
GlaxoSmithKline USA, United States of America (USA)	0.500000	0.04
Rutgers Health, United States of America (USA)	0.500000	0.04

Interested in Immunology?